IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3605
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$6M
J. Rodney Varner
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$GNPX Genprex, Inc. | 40 | 24 | 6 | 78 | - | - | -2182.2% | -470.3% | - | - | - | - | 0.0% | 364.0x | $6M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Genprex, Inc. (GNPX) receives a "Avoid" rating with a composite score of 39.5/100. It ranks #3605 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
J. Rodney Varner
Chief Executive Officer
Labor Force
20
24
25
23
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for GNPX
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for GNPX.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -2182.2% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 9yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags Genprex, Inc. with an Avoid rating, assigning a composite score of 39.5/100 and 1 out of 5 stars. Ranked #3605 of 7,333 stocks, GNPX falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Genprex, Inc. registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of -2182.2% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
GNPX registers a value score of just 6/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 5.26x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Genprex, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -470.3% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
GNPX shows strong momentum characteristics with a score of 78/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth data is not currently available, while a beta of 0.71 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
Genprex, Inc. registers a low stability score of 23/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 0.71 and a debt-to-equity ratio of 364.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
GNPX carries a short interest score of 62/100, indicating moderate short selling activity. This is a neutral reading — not enough to signal systemic bearishness, but worth monitoring. Specific risk factors include elevated leverage (D/E: 364.00x), micro-cap liquidity risk. At $6M market cap (micro-cap), Genprex, Inc. offers reasonable institutional liquidity.
Genprex, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3605 of 7,333 overall (51st percentile). Key comparisons include ROE of -2182.2% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While GNPX currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (6) would have the largest impact on the composite score.
ROE 87890% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 181900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Genprex, Inc. (GNPX) as Avoid with a composite score of 39.5/100 at a current price of $2.17. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in momentum (78th percentile) and investment (25th percentile), which together account for the majority of the composite score. Offsetting weakness in value (6th percentile) and stability (23th percentile) tempers our overall conviction. We assign a No Moat rating (10/100), High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Genprex, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 39.5/100 places it at rank #3605 in our full 7,333-stock universe. At $6M in market capitalization, Genprex, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (78th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Genprex, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $2.17, Genprex, Inc. is trading at a premium to fundamental value. Our value factor score of 6/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 5.3x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Positive momentum (78th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Avoid rating (composite 39.5/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (364% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Below-average quality (24th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
We assign a High uncertainty rating to Genprex, Inc.. Key risk factors include significant leverage (364% debt-to-equity), below-average price stability (23th percentile), weak quality scores (24th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: significant leverage (364% debt-to-equity); below-average price stability (23th percentile); weak quality scores (24th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 23th percentile and quality factor at the 24th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Genprex, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-2182.2%), elevated leverage (364% D/E), weak asset returns (ROA -470.3%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Genprex, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Genprex, Inc. receives a Avoid rating with a composite score of 39.5/100 (rank #3605 of 7,333). Our quantitative framework assigns a No Moat (10/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 31/100.
Our analysis does not support a constructive view on Genprex, Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Genprex, Inc. a meaningful economic moat, scoring 10/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and economic value creation (0/20). GM N/A vs sector 43%, OM N/A vs sector 1%. ROE proxy -2182.2% (sector -2.5%). These pillars form the core of Genprex, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and reinvestment efficiency (0/20). ROE proxy -2182.2% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Genprex, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 24/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -2182.2% and ROA of -470.3%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -2182.2% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 364%, which may limit financial flexibility. The sector median D/E is 0%, putting Genprex, Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Above 50MA
37.18%
Net New Highs
+51081
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1.5% on Wednesday. The Dow traded down 0.21% to 38,384.83 while the NASDAQ fell 1.53% to 15,272.34. The S&P 500 also fell, dropping, 1.02% to 4,874.63. Check This Out: Jim Cramer Says It's 'Still Not Too Late' To Buy This Energy Stock Leading and Lagging Sectors Real estate shares rose by 0.7% on Wednesday. In trading on Wednesday, communication services shares fell by 3.3%. Top Headline The Federal Reserve maintained interest rates between 5.25% and 5.5% Wednesday during its first meeting of 2024, aligning with market predictions. Equities Trading UP Ashland Inc. (NYSE: ASH) shares shot up 17% to $94.34 after the company reported mixed first-quarter financial results and issued guidance. Shares of Minim, Inc. (NASDAQ: MINM) got a boost, surging 65% to $4.18. David E. Lazar disclosed a 51% active stake in Minim Inc. Powell Industries, Inc. (NASDAQ: POWL) shares were also up, gaining 48% to $120.92 after the company reported better-than-expected first-quarter financial results and raised its quarterly dividend. Equities Trading DOWN Nuvve Holding Corp. (NASDAQ: NVVE) shares dropped 59% to $1.37. Nuvve announced pricing of $9.6 million underwritten public offering of 4.8 million shares ...
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA a
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that IP Australia, the Australian government agency responsible for administering Australia's intellectual property rights system, has issued a Notice of Acceptance, on February 5, 2026, of the Genprex patent application claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies fo
Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results. United Natural Foods posted adjusted earnings of 7 cents per share, compared to market estimates for a loss of 1 cent per share. The company’s quarterly sales came in at $7.78 billion, versus expectations of $7.87 billion, according to data from Benzinga Pro. United Natural Foods named Giorgio Matteo Tarditi as President and Chief Financial Officer. United Natural Foods shares dipped 15.2% to $12.61 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 115.2% to $4.24. Rail Vision announced first commercial installation of its AI-driven main line systems in a national railways line. Aptorum Group Limited (NASDAQ: APM) shares climbed 90.1% to $3.1750. Aptorum Group announced an agreement and plan of merger with YOOV Group Holding Ltd and a split-off agreement to separate its legacy business. NKGen Biotech, Inc. (NASDAQ: NKGN) gained 46.5% to $1.35. TRxADE HEALTH, Inc. (NASDAQ: MEDS) rose 39.2% to $11.19 after the company announced a special cash dividend of $8 per share. Airship AI Holdings, Inc. (NASDAQ: AISP) shares climbed 37.8% to $6.82. Airship AI Holdings shares jumped 200% on Tuesday after the company announced that it has been awarded a contract with the Department of Justice for its Acropolis Enterprise Sensor Management video and data management platform. Enviva Inc. (NYSE: EVA) rose 33% to $0.9854 after gaining 42% on Tuesday. American Public Education, Inc. (NASDAQ: APEI) gained 31.8% to $14.99 following upbeat quarterly results. Dada Nexus Limited (NASDAQ: DADA) climbed 30.6% to $2.5740. Dada Nexus said certain revenues and associated costs were overstated in past financial statements. Cemtrex, Inc. (NASDAQ: CETX) gained 30% to $4.4361. Cemtrex announced beta release of pioneering AI gun detection feature. Wave Life Sciences Ltd. (NYSE: WVE) gained 28.5% to $6.16 following upbeat quarterly results. Vincerx Pharma, Inc. (NASDAQ: VINC) shares gained 24.5% to $6.89. Vincerx will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024. XORTX Therapeutics Inc. (NASDAQ: XRTX) rose 24.2% to $5.85. CareMax, Inc. (NASDAQ: CMAX) gained 23.8% to ...
Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on revenue of $6.17 billion. AMD shares dipped 3.8% to $165.49 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 204% to $0.6049. Connexa said it has regained compliance with Nasdaq minimum shareholder equity rule. Minim, Inc. (NASDAQ: MINM) shares climbed 76.4% to $4.48. David E. Lazar disclosed a 51% active stake in Minim Inc. Powell Industries, Inc. (NASDAQ: POWL) shares gained 49% to $121.89 after the company reported better-than-expected first-quarter financial results and raised its quarterly dividend. Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) climbed 46.5% to $0.1180 after falling around 7% on Tuesday. Ashford Hospitality Trust, Inc. (NYSE: AHT) jumped 32% to $1.77. 2seventy bio, Inc. (NASDAQ: TSVT) rose 31.6% to $5.28. 2seventy Bio said it will focus exclusively on commercialization and development of Abecma and sell its R&D pipeline to Regeneron. Leerink Partners analyst Daina Graybosch upgraded 2seventy bio from Market Perform to Outperform and raised the price target from $5 to $18. Trinity Biotech plc (NASDAQ: TRIB) gained 29.5% to $0.5638. Trinity Biotech announced acquisition of the CGM assets of Waveform Technologies, Inc. Kuke Music Holding Limited (NYSE: KUKE) rose 23.7% to $1.25. Vaxart, Inc. (NASDAQ: VXRT) jumped 20.9% to $1.1850. B. Riley Securities analyst Mayank Mamtani upgraded Vaxart from Neutral to Buy and announced a $2 price target. Envirotech Vehicles, Inc. (NASDAQ: EVTV) gained 20.6% to $1.75. Ensysce Biosciences, Inc. (NASDAQ: ENSC) gained 19.6% to ...